Search Within

Roisin Eilish O'Cearbhaill

Formats
  1. Meeting Abstract (127)
  2. Journal Article (124)
  3. Review (9)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (272)
  2. GDMT, Medicine (272)
  3. Gynecologic Medicine Service (272)
  4. Gynecology Disease Management Team (272)
  5. Hematologic Malignancies, Division of (272)
  6. Solid Tumor Oncology Division (272)

More Groups

People
  1. Carol Aghajanian (99)
  2. Alexia Iasonos (75)
  3. Qin Zhou (68)
  4. Rachel Grisham (68)
  5. Dennis Chi (67)
  6. William Tew (66)

More People

Years
  1. 2025 (14)
  2. 2024 (30)
  3. 2023 (43)
  4. 2022 (31)
  5. 2021 (25)
  6. 2020 (41)

More Years

Publications
  1. Gynecologic Oncology (91)
  2. Journal of Clinical Oncology (45)
  3. International Journal of Gynecological Cancer (39)
  4. Annals of Oncology (13)
  5. Gynecologic Oncology Reports (11)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (98)
  2. American Society of Clinical Oncology (48)
  3. Lippincott Williams & Wilkins (40)
  4. American Association for Cancer Research (13)
  5. Oxford University Press (13)
  6. Elsevier B.V. (11)

More Publishers

Results (272)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – A plain language summary
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer
    Meeting Abstract

    Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors
    Meeting Abstract

    Spira, A. I.; Lee, E. K.; O'Cearbhaill, R. E.; LoRusso, P.; Falchook, G. S.; Patel, M. R.; Richardson, D. L.; Lu, W.; Marreddy, P.; Farrington, D. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial
    Journal Article

    Gupta, A.; O'Cearbhaill, R. E.; Block, M. S.; Hamilton, E.; Konner, J. A.; Knutson, K. L.; Potts, J.; Garrett, G.; Kenney, R. T.; Wenham, R. M.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Ocular side effects of anticancer agents used in the treatment of gynecologic cancers
    Review

    Crowley, F.; Broderick, S.; Francis, J. H.; O'Cearbhaill, R. E.; Canestraro, J.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer
    Journal Article

    Andres, S.; Finch, L.; Iasonos, A.; Zhou, Q.; Girshman, J.; Chhetri-Long, R.; Green, H.; Jang, D.; O'Cearbhaill, R.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities
    Journal Article

    Manning-Geist, B. L.; Sullivan, M. W.; Zhou, Q.; Iasonos, A.; Selenica, P.; Stallworth, C.; Liu, Y.; Long Roche, K.; Gordhandas, S.; Aghajanian, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
    Journal Article

    Valabrega, G.; Pothuri, B.; Oaknin, A.; Graybill, W. S.; Sánchez, A. B.; McCormick, C.; Baurain, J. F.; Tinker, A. V.; Denys, H.; O'Cearbhaill, R. E.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Redefining the standard of care for low-grade serous ovarian cancer
    Review

    Manning-Geist, B. L.; Cantor, T.; O'Cearbhaill, R. E.; Grisham, R. N.
    Clinical Advances in Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save